leadf
logo-loader
viewSareum Holdings PLC

Sareum looks towards clinical studies for novel autoimmune and cancer therapies

Sareum is looking to secure commercial licences for the late pre-clinical or early clinical stages of their development

Sareum Holdings PLC -
Sareum added both programmes (SDC-1801 for autoimmune diseases and SDC-1802 for cancer) are continuing to receive interest from international pharmas.

Sareum Holdings PLC (LON:SAR) is aiming for in-human trials by the end of 2020 for its novel molecules targeting autoimmune diseases and cancer.

The orally taken, once-daily treatments are based on its proprietary dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) programmes, which are in pre-clinical studies currently.

Sareum added both programmes (SDC-1801 for autoimmune diseases and SDC-1802 for cancer) are continuing to receive interest from international pharmas.

Tim Mitchell, chief executive, said: "We are very pleased with the progress of our proprietary dual TYK2/JAK1 programmes. 

“We believe these offer a novel oral immunotherapy approach to addressing unmet needs in autoimmune diseases and cancer and that their mechanism is gaining increasing interest from the pharmaceutical industry.

Sareum is looking to secure commercial licences for the late pre-clinical or early clinical stages of their development

Mitchell also remains hopeful that partner Sierra Oncology will be able to find the funds to develop cancer treatment molecule SRA737, especially after encouraging clinical results in June and good indications from pre-clinical combinations with other therapies.

Losses were £1.45mln after tax in the year to June, with cash in the bank of £0.92mln though that does not include a further £780,000 raised in July.

Quick facts: Sareum Holdings PLC

Price: 0.805 GBX

AIM:SAR
Market: AIM
Market Cap: £26.21 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Sareum Holdings PLC named herein, including the promotion by the Company of Sareum Holdings PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Sareum Holdings says Phase I clinical trials for CHK1 could potentially...

Tim Mitchell, chief executive officer at cancer drug discovery company Sareum Holdings (LON:SAR), talks to Proactive Investors about the progress achieved by all of its programmes in the half year ended December 31, 2015. He says Phase I clinical trials for CHK1, its most advanced...

on 02/24/2016

2 min read